Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
The International Journal of Artificial Organs|September 1, 1984
Heparin for hemodialysis: practical guidelines for administration and monitoringG Mingardi, N Perico, F Pusineri, et al.
Blood|August 15, 1996
In vitro transcription and translation inhibition by anti-promyelocytic leukemia (PML)/retinoic acid receptor alpha and anti-PML peptide nucleic acidC Gambacorti-Passerini, L Mologni, C Bertazzoli, et al.
Journal of Cardiovascular Risk|May 19, 2000
Plasminogen activator inhibitor-1 and carotid intima-media thickening in patients with newly detected primary hypertensionE Marchesi, A Martignoni, C Tinelli, et al.
Journal of the National Cancer Institute|January 29, 1999
In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitorP le Coutre, L Mologni, L Cleris, et al.
Hypertension (Dallas, Tex. : 1979)|November 1, 1994
Cardiovascular autonomic modulation in essential hypertension. Effect of tiltingA Radaelli, L Bernardi, F Valle, et al.
American Journal of Hypertension|June 1, 1991
Double-blind comparison of perindopril and captopril in hypertension. Effects on left ventricular morphology and functionA M Grandi, A Venco, F Barzizza, et al.
Cardiologia (Rome, Italy)|December 1, 1991
[The variability of the heart rate, arterial pressure and peripheral circulation as the indices of autonomic control in essential hypertension]A Radaelli, L Ricordi, D Corbellini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 1996
Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patientsS Dermime, C Bertazzoli, E Marchesi, et al.
British Journal of Haematology|April 12, 2001
Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of diseaseC Gambacorti-Passerini, R Barni, E Marchesi, et al.
Melanoma Research|November 1, 1992
Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot studyF Belli, F Arienti, L Rivoltini, et al.
Pageof 7